RECRUITING

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to learn about the best approach to sample patients with known or suspected Barrett's esophagus (BE) by comparing the standard Seattle biopsy protocol to sampling using wide area transepithelial sampling (WATS3D). Barrett's esophagus is a common condition that is used to spot patients at increased risk of developing a type of cancer in the esophagus (swallowing tube) called esophageal adenocarcinoma. The 5-year survival rate is as low as 18% for patients who get esophageal adenocarcinoma, but the rate may be improved if the cancer is caught in its early stages. Barrett's esophagus can lead to dysplasia, or precancerous changes, which occurs when cells look abnormal but have not developed into cancer. If the abnormal cells increase from being slightly abnormal (low-grade dysplasia), to being very abnormal (high-grade dysplasia), the risk of developing cancer (esophageal adenocarcinoma) goes up. Therefore, catching dysplasia early is very important to prevent cancer. Endoscopic surveillance is a type of procedure where endoscopists run a tube with a light and a camera on the end of it down a patients throat and remove a small piece of tissue. The piece of tissue, called a biopsy, is about the size of the tip of a ball-point pen and is checked for abnormal cells and cancer cells. Patients are being asked to be in this research study because they have been diagnosed with BE or suspected to have BE, and will need an esophagogastroduodenoscopy (EGD). Patients with BE undergo sampling using the Seattle biopsy protocol during which samples are obtained from the BE in a four quadrant fashion every 2 cm along with target biopsies from any abnormal areas within the BE. Another sampling approach is WATS3D which utilizes brushings from the BE. While both of these procedures are widely accepted approaches to sampling patients with BE during endoscopy, there is not enough research to show if one is better than the other. Participants in this study will undergo sampling of the BE using both approaches (Seattle biopsy protocol and WATS-3D); the order of the techniques will be randomized. Up to 2700 participants will take part in this research. This is a multicenter study involving several academic, community and private hospitals around the country.

Official Title

A Multicenter Randomized Trial of Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance (The SWAT-BE Study)

Quick Facts

Study Start:2022-10-03
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05530343

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Undergoing surveillance endoscopy for a diagnosis of non-dysplastic Barrett's esophagus (NDBE, based on last endoscopic procedure; patients with prior history of low-grade dysplasia/indefinite for dysplasia with NDBE at last endoscopy can be included)
  2. * Barrett's esophagus (BE) length of at least M1
  3. * English and Spanish speaking
  4. * Able to comprehend and complete the consent form
  5. * Age18-89 years
  6. * Life-expectancy of at least 2 years
  7. * Undergoing endoscopy for screening of BE
  8. * BE length of at least M1
  9. * English and Spanish speaking
  10. * Able to comprehend and complete the consent form
  11. * Age 18-89 years
  12. * Expected life-expectancy of at least 2 years
  1. * BE patients undergoing surveillance or evaluation for endoscopic eradication therapy (EET) for prior diagnosis of BE related dysplasia or esophageal adenocarcinoma (EAC)
  2. * Active erosive esophagitis with LA Grade B or higher
  3. * Esophageal varices
  4. * Prior history of EET
  5. * Prior history of esophageal or gastric surgery, except for uncomplicated fundoplication
  6. * Pregnancy
  7. * BE patients undergoing surveillance or evaluation for EET for prior diagnosis for BE-related dysplasia or EAC
  8. * Active erosive esophagitis with LA Grade B or higher
  9. * Esophageal varices
  10. * Prior history of esophageal or gastric surgery, except for uncomplicated fundoplication
  11. * Pregnancy

Contacts and Locations

Study Contact

Alexa R DeBord, MS
CONTACT
303-724-0432
alexa.debord@cuanschutz.edu
Sandra Boimbo, MPH
CONTACT
303-724-8892
sandra.boimbo@cuanschutz.edu

Principal Investigator

Sachin Wani, MD
PRINCIPAL_INVESTIGATOR
University of Colorado - Anschutz Medical Campus

Study Locations (Sites)

Arizona Centers of Digestive Health
Gilbert, Arizona, 85295
United States
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90024
United States
Kaiser Permanente
Oakland, California, 94611
United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045
United States
Connecticut Clinical Research Institute
Bristol, Connecticut, 06010
United States
Suncoast Endoscopy of Sarasota
Sarasota, Florida, 34239
United States
Northwestern University
Chicago, Illinois, 60611
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
United States
Weill Cornell Medicine
New York, New York, 10065
United States
University of Rochester
Rochester, New York, 14642
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Geisinger Medical Center
Danville, Pennsylvania, 17822
United States
Gastrointestinal Associates, PC
Knoxville, Tennessee, 37909
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Sachin Wani, MD, PRINCIPAL_INVESTIGATOR, University of Colorado - Anschutz Medical Campus

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-03
Study Completion Date2026-03

Study Record Updates

Study Start Date2022-10-03
Study Completion Date2026-03

Terms related to this study

Keywords Provided by Researchers

  • Barrett's Esophagus
  • Esophageal Adenocarcinoma
  • Dysplasia

Additional Relevant MeSH Terms

  • Barrett Esophagus
  • Barretts Esophagus With Dysplasia
  • Esophageal Adenocarcinoma